The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holmes, C. H.
Right arrow Articles by Tanner, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmes, C. H.
Right arrow Articles by Tanner, M. J.

The Journal of Immunology, Vol 144, Issue 8 3099-3105, Copyright © 1990 by American Association of Immunologists

ARTICLES

Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy

CH Holmes, KL Simpson, SD Wainwright, CG Tate, JM Houlihan, IH Sawyer, IP Rogers, FA Spring, DJ Anstee and MJ Tanner
University Department of Obstetrics and Gynaecology, Bristol Maternity Hospital, England.

The expression of decay accelerating factor (DAF) was investigated in human fetal and extra-fetal tissues using a panel of mAb directed against different epitopes on the DAF molecule. By immunostaining, extensive reactivity was observed on the placental trophoblast epithelium and this was confined exclusively to sites of direct contact with maternal blood and tissues at the fetomaternal interface. Within the fetus, by contrast, very little staining was observed especially on hemopoietic cell populations in the developing liver. The antibodies identified a component of 70,000 m.w., comigrating on SDS-PAGE with red cell DAF, on isolated trophoblast membranes and an apparently quantitative increase in the expression of DAF was observed during placental development. Northern analysis using a DAF cDNA clone revealed 1.5-, 1.6-, and 2.2-kb mRNA transcripts typical of DAF in mRNA prepared from whole term placentae and from purified trophoblast cells. DAF appears to be preferentially expressed at the fetomaternal interface during development and may function specifically to inhibit amplification convertases formed at this site either directly or indirectly as a result of maternal complement activation. This molecule may play an important role in protecting the semiallogeneic human conceptus from maternal C-mediated attack.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
I. Guleria and M. H. Sayegh
Maternal Acceptance of the Fetus: True Human Tolerance
J. Immunol., March 15, 2007; 178(6): 3345 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Martinez de la Torre, C. Buracchi, E. M. Borroni, J. Dupor, R. Bonecchi, M. Nebuloni, F. Pasqualini, A. Doni, E. Lauri, C. Agostinis, et al.
Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6
PNAS, February 13, 2007; 104(7): 2319 - 2324.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
A.-H. Zarnani, S.-M. Moazzeni, F. Shokri, M. Salehnia, and M. Jeddi-Tehrani
Kinetics of murine decidual dendritic cells
Reproduction, January 1, 2007; 133(1): 275 - 283.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M.P. Smith, G.R. Flannery, B.J. Randle, J.M. Jenkins, and C.H. Holmes
Leukocyte origin and profile in follicular aspirates at oocyte retrieval
Hum. Reprod., December 1, 2005; 20(12): 3526 - 3531.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
R Bulla, F Fischetti, F Bossi, and F Tedesco
Feto-maternal immune interaction at the placental level
Lupus, September 1, 2004; 13(9): 625 - 629.
[Abstract] [PDF]

Home page
 Mol Hum ReprodHome page
V. M. Abrahams, S. L. Straszewski-Chavez, S. Guller, and G. Mor
First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis
Mol. Hum. Reprod., January 1, 2004; 10(1): 55 - 63.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
V. M. Holers, G. Girardi, L. Mo, J. M. Guthridge, H. Molina, S. S. Pierangeli, R. Espinola, L. E. Xiaowei, D. Mao, C. G. Vialpando, et al.
Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss
J. Exp. Med., January 22, 2002; 195(2): 211 - 220.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
C. Xu, D. Mao, V. M. Holers, B. Palanca, A. M. Cheng, and H. Molina
A Critical Role for Murine Complement Regulator Crry in Fetomaternal Tolerance
Science, January 21, 2000; 287(5452): 498 - 501.
[Abstract] [Full Text]

Home page
 Reproductive SciencesHome page
I. K. Zarkadis, A. Omigbodun, A. Forson, P. Ziolkiewicz, T. Kinoshita, J. D. Lambris, and C. Coutifaris
Differentiation-Dependent Changes in Human Trophoblast Expression of Decay-Accelerating Factor Are Modulated by 3',5' Cyclic Adenosine Monophosphate
Reproductive Sciences, January 1, 1997; 4(1): 47 - 53.
[Abstract] [PDF]

Home page
 J. Cell Sci.Home page
J Walker, J Watson, C Holmes, A Edelman, and G Banting
Production and characterisation of monoclonal and polyclonal antibodies to different regions of the cystic fibrosis transmembrane conductance regulator (CFTR): detection of immunologically related proteins
J. Cell Sci., January 6, 1995; 108(6): 2433 - 2444.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.